Vilazodone Hydrochloride

Depression
Treatment
1 FDA approval
20 Active Studies for Vilazodone Hydrochloride

What is Vilazodone Hydrochloride

VilazodoneThe Generic name of this drug
Treatment SummaryVilazodone is a medication used to treat depression. It works by targeting both serotonin transporters and serotonin receptors in the brain. It is associated with fewer side effects such as sexual dysfunction and weight gain when compared to other antidepressant medications. It was approved by the FDA in 2011.
Viibrydis the brand name
Vilazodone Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Viibryd
Vilazodone
2011
35

Approved as Treatment by the FDA

Vilazodone, otherwise called Viibryd, is approved by the FDA for 1 uses like Depression .
Depression

Effectiveness

How Vilazodone Hydrochloride Affects PatientsVilazodone boosts serotonin levels in the brain by blocking the removal of serotonin, while also activating serotonin-1A receptors. This combination of effects has earned vilazodone the nickname of SPARI, which stands for selective partial agonist and reuptake inhibitor.
How Vilazodone Hydrochloride works in the bodyVilazodone works on two levels to reduce depressive symptoms. It blocks the reuptake of serotonin in the brain, keeping more of the feel-good hormone in circulation. It also activates the 5HT-1A receptor, which is thought to be linked to decreased depression.

When to interrupt dosage

The advised dosage of Vilazodone Hydrochloride is reliant upon the specified condition. The amount of dosage fluctuates as per the method of administration (e.g. Tablet - Oral or Tablet, film coated - Oral) noted in the table beneath.
Condition
Dosage
Administration
Depression
40.0 mg, 10.0 mg, 20.0 mg,
Tablet - Oral, Tablet, film coated - Oral, , Tablet, film coated, Kit; Tablet - Oral, Kit, Kit - Oral, Oral, Tablet, Kit; Tablet

Warnings

Vilazodone Hydrochloride Contraindications
Condition
Risk Level
Notes
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
There are 20 known major drug interactions with Vilazodone Hydrochloride.
Common Vilazodone Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Methylene blue
Major
Vilazodone may increase the serotonergic activities of Methylene blue.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Vilazodone is combined with Oliceridine.
Sodium oxybate
Major
Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Vilazodone Hydrochloride Toxicity & Overdose RiskThere have not been any studies done on vilazodone in pregnant women, but animal studies have shown that it could lead to reduced fetal weight, increased mortality, delayed development, and decreased fertility at doses much higher than the recommended amount for humans. Also, there have been cases of infants and newborns exposed to SSRIs and SNRIs who experienced problems such as breathing difficulties, seizures, and trouble regulating their body temperature. It is not known if vilazodone is present in breast milk, but animal studies have shown that it is present in rats. Before deciding to breastfeed while taking vilazodone, the benefits

Vilazodone Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Vilazodone Hydrochloride?

186 active clinical trials are examining the potential of Vilazodone Hydrochloride to alleviate symptoms of Depression.
Condition
Clinical Trials
Trial Phases
Depression
193 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4, Early Phase 1

Vilazodone Hydrochloride Reviews: What are patients saying about Vilazodone Hydrochloride?

4.7Patient Review
2/7/2013
Vilazodone Hydrochloride for Major Depressive Disorder
I thought this drug was quite effective. I had better results with Wellbutrin, but it also came with more side effects.
4.7Patient Review
6/17/2018
Vilazodone Hydrochloride for Major Depressive Disorder
I found that 20mg was the perfect amount for me, giving me lots of energy and helping me focus. I tried going up to 40mg, but found that my anxiety increased too much.
4.3Patient Review
4/26/2014
Vilazodone Hydrochloride for Major Depressive Disorder
I experienced a lot of muscle cramps when I first started taking this medication, but they quickly subsided. I've been generally pleased with its effectiveness in treating my depression.
4Patient Review
11/29/2012
Vilazodone Hydrochloride for Major Depressive Disorder
I was always tired, even after working out at the gym. I had low libido and difficulties with erections, plus my muscles would always get fatigued easily. If I missed a dose, I would have horrible dreams. And if I drank alcohol while taking the medication, I would feel really awful. On the bright side, I didn't experience many visual problems.
4Patient Review
1/22/2013
Vilazodone Hydrochloride for Major Depressive Disorder
Viibryd can cause some serious problems if taken alongside Straterra. I would recommend avoiding this combination as it can lead to hospitalization due to major depression.
3.7Patient Review
11/22/2012
Vilazodone Hydrochloride for Major Depressive Disorder
I experienced a lot of side effects while taking this drug, including tingling cravings (both at the beginning and the end), diarrhea, and sexual dysfunction.
3.7Patient Review
9/22/2011
Vilazodone Hydrochloride for Major Depressive Disorder
3Patient Review
8/1/2012
Vilazodone Hydrochloride for Major Depressive Disorder
This treatment is okay. It helped a little bit, but I didn't see a huge difference.
2.3Patient Review
8/28/2013
Vilazodone Hydrochloride for Major Depressive Disorder
I developed a burning, peeling rash after only three weeks of use. Six weeks later and I'm still dealing with the same issue. Additionally, I now have mouth sores that aren't healing. The doctor was no help whatsoever and just told me to stop taking the medication. What am I supposed to do now?
2.3Patient Review
3/19/2014
Vilazodone Hydrochloride for Major Depressive Disorder
This medication did not help me at all. If anything, it made things worse.
2Patient Review
9/19/2022
Vilazodone Hydrochloride for Major Depressive Disorder
I'm three weeks in and I don't feel like this medication has helped me mood-wise at all. If anything, it's made me more tired, less interested in sex, and nauseous. I'm only on a 10 MG dose, so I don't think increasing the dosage would help matters.

Patient Q&A Section about vilazodone hydrochloride

What kind of antidepressant is vilazodone?

"Vilazodone is used to treat depression and it works by preventing the reuptake of serotonin in the brain." - Anonymous Online Contributor

Unverified Answer

Is vilazodone a good antidepressant?

"The evidence does not support the use of vilazodone for routine depression treatment. It is more expensive than generic alternatives, and no more effective for moderate to severe depression than other medications." - Anonymous Online Contributor

Unverified Answer

What is vilazodone used for?

"Vilazodone is used to treat depression in adults by increasing the activity of a chemical called serotonin in the brain." - Anonymous Online Contributor

Unverified Answer

What are the side effects of vilazodone?

"You may experience diarrhea, nausea, vomiting, dizziness, or trouble sleeping. If you experience any of these effects for an extended period of time, or if they worsen, contact your doctor or pharmacist. Keep in mind that your doctor prescribed this medication because they believe that the benefits outweigh the risks of side effects." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Vilazodone Hydrochloride

Image of Laureate Institute for Brain Research in Tulsa, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Active Low Intensity Focused Ultrasound (LIFU)for Depression

Tulsa, OK
18 - 65
All Sexes
The investigators propose to use low-intensity transcranial focused ultrasound (LIFU), a novel neuromodulation method, to probe the causal involvement of individually defined components of an anteromedial brain circuit in the processing of self-referential thoughts, and the production of repetitive negative thinking (RNT), a prominent transdiagnostic manifestation with adverse clinical consequences. The investigators hypothesize that real vs. sham low-intensity sonication of individually-defined anteromedial structures connecting medial orbitofrontal and anterior cingulate cortices with ventral striatum and anterior thalamus will show reduced initiation or maintenance of RNT as measured by (1) Brief State Rumination Inventory (BSRI) scores and distress associated to repetitive negative thoughts, and (2) improvement of the affective valence associated to self-referential adjectives, and that these changes will be associated with decreased connectivity between structures mentioned above. The present early feasibility study is an initial step that aims to determine its feasibility and help with the planning of a larger study addressed at actual hypothesis testing.
Recruiting
1 Prior Treatment
Laureate Institute for Brain Research
Have you considered Vilazodone Hydrochloride clinical trials? We made a collection of clinical trials featuring Vilazodone Hydrochloride, we think they might fit your search criteria.
Image of National Institutes of Health Clinical Center in Bethesda, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

Activefor Depression

Bethesda, MD
13 - 17
All Sexes
Background: Major depressive disorder (MDD) is one of the most impairing medical conditions in the world. Medication and some kinds of talk therapy are standard treatments for teens with MDD, but these do not work well for everyone. Transcranial magnetic stimulation (TMS) has been approved to treat MDD in adults. TMS might help adolescents, too. Objective: To test TMS combined with cognitive behavioral therapy (CBT) in teens with MDD. Eligibility: People aged 13 to 17 years with MDD that has not responded to treatment. Design: Participants will be screened. They will have a physical exam and psychiatric evaluation. They will have an MRI scan and a test of their heart function. They will enroll in 2 NIH protocols (01-M-0254 and 18-M-0037). For 2 to 6 weeks, participants will have weekly CBT, a kind of talk therapy. They will taper off of their psychiatric medicines. For 2 weeks, participants will come to the clinic every weekday. They will receive 3 or 4 sessions of TMS on each of those days. A wire coil will be held on their scalp. A brief electrical current in the coil creates a magnetic pulse that affects brain activity. They will receive 30 TMS pulses in 10-second bursts; these will be repeated 60 times in each 15-minute session. Participants may hear a click and feel a pulling sensation under the coil. They may feel their muscles twitch. Each day, they will have tests of concentration, thinking, and memory. Some may have a 3rd week of TMS. Participants will remain in the study for 5 more weeks. They will begin taking their medications again.
Phase 2
Waitlist Available
National Institutes of Health Clinical CenterDaniel S Pine, M.D.
Image of Mood Disorders Program in Halifax, Canada.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Ketaminefor Bipolar Disorder

Halifax, Canada
18 - 65
All Sexes
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later. The main problem with IV ketamine for TRD is that the effect is short-lived, lasting only days to 1 or 2 weeks. Furthermore, IV ketamine is a resource-intensive treatment, and the safety of long-term, repeated use for depression is unknown. To provide this treatment in a safe and cost-effective way, Investigators must allocate it efficiently to those patients who have the greatest need and probability of benefit. Therefore, this project aims to find clinical features (signs, symptoms, and parts of a patient's history) that will help predict which patients are most likely to respond to a single dose of IV ketamine for TRD. This will help guide patient selection and triaging. Investigators will recruit 40 participants with TRD over one year, and randomize them to one of two conditions (ketamine followed by an active placebo 3-weeks later, or vice versa). With clinical data collected through detailed interviews and questionnaires, this study design will let us evaluate how well such factors predict (A) rapid response at 24-hours, and (B) sustained response at 7 and 14 days.
Phase 3
Waitlist Available
Mood Disorders ProgramAbraham Nunes MD PhD MBA FRCPC
Have you considered Vilazodone Hydrochloride clinical trials? We made a collection of clinical trials featuring Vilazodone Hydrochloride, we think they might fit your search criteria.
Image of University of California Los Angeles (UCLA) in Los Angeles, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Left DLPFC TDCSfor Depression

Los Angeles, CA
20 - 55
All Sexes
Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and using a 9-volt battery to cause a small amount of electricity to pass through parts of the brain. Depending on the direction of electrical flow, tDCS can make brain cells (neurons) more likely or less likely to generate their own electrical signals. When evaluated as a treatment, tDCS is typically done in daily sessions over a period of two weeks. One of the challenges of tDCS is to work out the best possible positioning of electrodes and direction of electricity flow to gradually cause lasting changes in brain activity in ways that might be expected to improve depression. To address this challenge, the investigators are using MRI to take pictures of the brain during tDCS. This data will help us better understand the short-term effects of tDCS in depression and help us learn how to customize future treatments to cause a lasting beneficial response. Patients with depression between the ages of 20-55 years are eligible to take part in this research. Potential participants will undergo: An assessment to confirm eligibility. This will take place over a secure videoconference call lasting no more than 3 hours. Two in-person study visits lasting 30 min and 2-1/2 hours respectively. In the first visit, the investigators will use the MRI to take a picture of the brain and head structure to determine appropriate locations for placing the tDCS electrodes at the start of the second visit. Following electrode placement, an MRI scan will be performed to take pictures of the brain during tDCS. Depending on the study arm, Participants may receive 'active' or 'sham' tDCS. The 'sham' condition is identical to the 'active' tDCS in every way except that it involves minimal tDCS and is designed to help rule out effects unrelated to the administered tDCS electricity. Participants may also be asked to perform a mental task during MRI. All participants will be compensated $150 + parking upon completion of all study-visits.
Recruiting
Has No Placebo
University of California Los Angeles (UCLA)Mayank A Jog, PhD
Have you considered Vilazodone Hydrochloride clinical trials? We made a collection of clinical trials featuring Vilazodone Hydrochloride, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top